Selank (Tuftsin Analogue)
Overview
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the immunomodulatory tetrapeptide tuftsin, extended with Pro-Gly-Pro to improve stability. In research it is studied as an anxiolytic that works through the GABAergic system without sedation, together with enkephalinase-inhibiting and immunomodulatory effects. It is typically delivered intranasally and is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 129954-34-3 |
| Class | Synthetic tuftsin analogue (heptapeptide) |
| Amino-acid sequence | H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH |
| One-letter code | TKPRPGP (7 aa) |
| Molecular formula | C₃₃H₅₇N₁₁O₉ |
| Molecular weight | ≈ 751.9 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Synthetic tuftsin analogue
- Origin
- Tuftsin (IgG Fc-derived tetrapeptide) + Pro-Gly-Pro
- Research status
- Preclinical and clinical (Eastern Europe)
- Study routes
- Intranasal (primary), IV, IM
- Half-life
- ≈ 20 min (intranasal)
- Key feature
- Anxiolytic without sedation
Mechanism of Action
Selank is a stabilised analogue of tuftsin. Its anxiolytic effect is studied as a benzodiazepine-independent modulation of the GABAergic system, and it also inhibits the enzyme that breaks down enkephalins (raising Met-enkephalin) and influences serotonin and dopamine systems — a profile associated with calming effects that do not cause the sedation or dependence of classic anxiolytics.
| Component | Detail |
|---|---|
| Primary target | GABAergic system (benzodiazepine-independent) |
| Enkephalinase inhibition | Neutral-endopeptidase inhibition → increased Met-enkephalin |
| Secondary targets | Serotonin (5-HT₁A/5-HT₂) and dopamine (D₂) systems |
| Immunomodulation | Retains tuftsin-like immune-signalling activity |
| BDNF | Moderate influence on neurotrophic signalling |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 20 min (intranasal) |
| Bioavailability (intranasal) | High — direct nose-to-brain delivery |
| Metabolism | Proteolytic cleavage by exopeptidases |
| Route of administration | Intranasal, IV, IM |
| Elimination | Renal (peptide fragments) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Rodent anxiety models | Anxiolytic activity without sedation | Selank preclinical literature |
| Cognition / stress models | Cognitive and anti-stress effects | Selank preclinical literature |
| Clinical anxiety observation | Generalized-anxiety research | Selank clinical literature (Eastern Europe) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Anxiolytic without sedation | rodent anxiety models | Selank literature |
| Immunomodulatory (tuftsin-like) activity | immune models | Selank literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 200–600 µg per dose (intranasal), in study protocols |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Storage (lyophilized) | −20°C, protected from light |
| Storage (reconstituted) | 2–8°C, up to ~7 days |
| Do not use | If the solution is cloudy or contains particulates |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Tolerability | Well tolerated in reported studies |
| Sedation / dependence | Not reported (a stated advantage over classic anxiolytics) |
| Local (intranasal) | Mild, transient nasal irritation possible |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white lyophilized powder |
| Solubility (water) | Freely soluble |
| pH (reconstituted) | 5.0–7.0 |
| Light sensitivity | Moderate |
| Stability (lyophilized) | ≥ 24 months at −20°C |
Synthesis & Manufacturing
Selank is a 7-residue peptide made by Fmoc solid-phase synthesis; its three prolines and the basic lysine/arginine residues shape coupling, and it has no oxidation-sensitive residues.
| Step | Detail |
|---|---|
| Strategy | Fmoc solid-phase peptide synthesis |
| Resin | Wang resin (C-terminal acid) |
| Coupling | HBTU / HOBt with DIPEA |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
- Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
- Critical quality attributes: correct molecular weight and low deletion-peptide content. No oxidation-sensitive residues; a robust, proline-rich peptide.
Analytical Methods
| Method | Parameter | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| HPLC retention | C18, reversed-phase TFA/ACN gradient | Single main peak |
| ESI-MS (positive mode) | Identity / mass | [M+H]⁺ ≈ 752 Da |
| MALDI-TOF | Mass confirmation | [M+H]⁺ ≈ 752 Da |
| Amino-acid analysis | Composition | Consistent with the stated sequence |
| LC-MS (extracted ion) | Deletion-peptide impurities | Within specification |
| Karl Fischer | Water content | < 6% |
| LAL assay | Endotoxin | Within specification |
| Ion chromatography | Residual TFA | < 500 ppm |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
- Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 752 Da). No oxidation-sensitive residues; a robust, proline-rich peptide.
Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized, −20°C, dark | ≥ 24 months | No significant degradation (purity > 97%) |
| Lyophilized, 2–8°C, dark | ≥ 12 months | Minimal degradation (purity > 95%) |
| Lyophilized, 25°C (accelerated) | 3 months | < 5% degradation |
| Reconstituted, 2–8°C, dark | 7–14 days | Minor degradation |
| Reconstituted, 25°C | 24–48 h | Use promptly |
| Light exposure (ICH Q1B) | 1.2 M lux·h | Generally light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable — aliquot to avoid repeats |
- Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
- Minimise freeze-thaw cycles; aliquot material used across many sessions.
- Key factor: No oxidation-sensitive residues; a robust, proline-rich peptide.
Selected References
- Selank (tuftsin analogue) anxiolytic and immunomodulatory research literature.
- Reviews of tuftsin-derived regulatory peptides.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Selank — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
